Literature DB >> 10029245

Impact of HIV type 1 subtype variation on viral RNA quantitation.

B Parekh1, S Phillips, T C Granade, J Baggs, D J Hu, R Respess.   

Abstract

We evaluated the performance of three HIV-1 RNA quantitation methods (Amplicor HIV-1 MONITOR-1.0, NASBA, and Quantiplex HIV RNA 2.0 [branched DNA (bDNA)]) using plasma specimens (N = 60) from individuals from Asia and Africa infected with one of three HIV-1 subtypes (A, Thai B [B'] or E; N = 20 each). Our results demonstrate that of the 20 subtype A specimens, 19 were quantifiable by the bDNA assay compared with 15 by the MONITOR-1.0 and 13 by NASBA. Of those quantifiable, the mean log10 difference was 0.93 between bDNA and MONITOR-1.0 and 0.46 between bDNA and NASBA. For subtype B' specimens, the correlation among methods was better with only 2 specimens missed by NASBA and 3 by the bDNA assay. However the missed specimens had viral burden near the lower limit (1000 copies/ml) for these assays. For the 20 subtype E specimens, MONITOR-1.0 and NASBA quantified RNA in 17 and 14 specimens, respectively, as compared with 19 specimens quantified by the bDNA assay. The correlation among different assays, especially between bDNA/NASBA and MONITOR-1.0/NASBA, was poor, although the mean log10 difference for subtype E specimens was 0.4 between bDNA and MONITOR-1.0 and only 0.08 between bDNA and NASBA. The addition of a new primer set, designed for non-B HIV-1 subtypes, to the existing MONITOR assay (MONITOR-1.0+) resulted in RNA detection in all 60 specimens and significantly improved the efficiency of quantitation for subtypes A and E. Our data indicate that HIV-1 subtype variation can have a major influence on viral load quantitation by different methods. Periodic evaluation and modification of these quantitative methods may be necessary to ensure reliable quantification of divergent viruses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029245     DOI: 10.1089/088922299311556

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

1.  Comparison of LCx with other current viral load assays for detecting and quantifying human immunodeficiency virus type 1 RNA in patients infected with the circulating recombinant form A/G (CRF02).

Authors:  Alessandra Amendola; Licia Bordi; Claudio Angeletti; Enrico Girardi; Giuseppe Ippolito; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Assessment of agreement between the AMPLICOR HIV-1 MONITOR test versions 1.0 and 1.5.

Authors:  Charles E Hill; Alicia M Green; Jessica Ingersoll; Kirk A Easley; Frederick S Nolte; Angela M Caliendo
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

3.  Comparison of the sensitivities and viral load values of the AMPLICOR HIV-1 MONITOR version 1.0 and 1.5 tests.

Authors:  Angela M Caliendo; Jessica Ingersoll; Alicia M Green; Frederick S Nolte; Kirk A Easley
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

4.  Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0.

Authors:  P Swanson; V Soriano; S G Devare; J Hackett
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

5.  Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma.

Authors:  Vincent Foulongne; Brigitte Montes; Marie-Noelle Didelot-Rousseau; Michel Segondy
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

Authors:  S Emery; S Bodrug; B A Richardson; C Giachetti; M A Bott; D Panteleeff; L L Jagodzinski; N L Michael; R Nduati; J Bwayo; J K Kreiss; J Overbaugh
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

7.  Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.

Authors:  M J Gonzales; R N Machekano; R W Shafer
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

8.  Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa.

Authors:  N Vidal; M Peeters; C Mulanga-Kabeya; N Nzilambi; D Robertson; W Ilunga; H Sema; K Tshimanga; B Bongo; E Delaporte
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

9.  Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants.

Authors:  Africa Holguín; Marisa López; Mar Molinero; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

10.  Multicenter evaluation of the performance characteristics of the NucliSens HIV-1 QT assay used for quantitation of human immunodeficiency virus type 1 RNA.

Authors:  Christine C Ginocchio; Marti Kemper; Kathleen A Stellrecht; Donald J Witt
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.